HOME >> MEDICINE >> NEWS
Timing of women's labor may determine effectiveness of pain medication

WINSTON-SALEM, N.C. Natural daily body rhythms may influence the effectiveness of spinal-epidural pain medication for women in labor, according to new research from Wake Forest University Baptist Medical Center. The study found that women who had day labor got longer pain relief than women with night labor with the same amount of labor pain medicine.

"Our research shows that the time of day that the medication is delivered is important in determining its effectiveness," said Peter H. Pan, M.D., an obstetrical anesthesiologist. "In the future, doctors may consider time of day, as well as patient's weight and other factors, when determining the best dose or method of drug delivery."

The study's goal was to determine if the body's natural internal rhythms can affect the effectiveness of pain medication for laboring women. The study, reported in the current issue of Anesthesiology, involved 77 women who were in labor with their first babies and requested spinal-epidural pain medication.

The research is part of the field of chronobiology that studies biologic rhythms. These rhythms include the circadian rhythm, the 24-hour body clock, and the ultradian rhythm, shorter-than-24-hour-cycles, which determine sleeping and eating patterns and can also affect blood pressure, heart rate and body temperature. Some rhythms are controlled by sunlight and others are controlled internally.

The researchers found that women who labored between noon and 6 p.m. got an average of 27 percent longer pain relief from a single dose of the spinal-epidural medication fentanyl than women whose labor was between 8 p.m. and 2 a.m. Fentanyl is one of the commonly used drugs for labor pain relief in the United States. However, this is one of the first studies to examine whether there are chronobiological variations in its effectiveness for labor pain relief.

"The right treatment given at the wrong time can be ineffective or create a crisis of escalating
'"/>

Contact: Karen Richardson
krchrdsn@wfubmc.edu
336-716-4453
Wake Forest University Baptist Medical Center
15-Sep-2005


Page: 1 2

Related medicine news :

1. Timing of radiation treatments for colon cancer may need adjusting, Jefferson researchers say
2. Timing possible treatments against Alzheimers disease
3. Timing of introduction of gluten into infants diet associated with appearance of celiac disease
4. Moderate drinking lowers womens risk of heart attack
5. Prioritizing womens health
6. Updated guidelines advise focusing on womens lifetime heart risk
7. Extra cortisol protects womens mood under stress
8. Finger length ratio may predict womens sporting prowess
9. Weight worries affect womens motivation to stay smoke-free after pregnancy
10. Target womens depression to reduce disability from chronic conditions, suggests study
11. Race and income converge to shape womens experiences with advanced breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Timing women labor may determine effectiveness pain medication

(Date:5/29/2015)... Clarkston, Metamora, Michigan (PRWEB) May 29, 2015 ... vulvar region and can cause significant physical, sexual, and ... major life altering disorder of Vulvodynia. The actual diagnosis ... Women’s Excellence in Endometriosis, they realize that this problem ... patient is experiencing any of these symptoms, they need ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 For the ... (USAU) to bring the Denver youth ultimate community an opportunity ... learning and individual improvement. The mission of the USAU Nike ... boys and girls to improve, build character, and make lifelong ... for boys and girls of all skill and ability levels, ...
(Date:5/29/2015)... External Counterpulsation, also known as EECP ... patients. The Heart Fit Clinic is the first clinic in ... review from patients who are now completing treatment. , ... treatments of ECP treatment and received great results. His ... does the clinic perform this non-surgical treatment for heart disease, ...
(Date:5/29/2015)... An organizational consultant and part-time college professor, Dr. ... and may be suffering from early dementia. He is ... and in his uncertain relationship with his wife Addie. ... with corporate and government movers and shakers as they ... around him are being diagnosed with Alzheimer’s, Ben wonders ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Testosterone Centers of ... DFW area, is opening a new center in the Mid-Cities ... rest of the Mid Cities. Located on the south side ... in Hurst, the new testosterone center will open in May ... who suffer from low testosterone. , Like TCT’s other testosterone ...
Breaking Medicine News(10 mins):Health News:US Sports Camps, Nike Sports Camps, and USA Ultimate Host Third Summer of Ultimate Camp in Denver 2Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2Health News:‘Forgetful’ Professor Struggles With Dementia in Compelling New Novel 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 3
(Date:5/29/2015)... Lilly and Company (NYSE: LLY ) and AstraZeneca ... entered into a clinical trial collaboration to evaluate the ... checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... planned study will assess the combination as a treatment ... Phase I study is expected to establish the safety ...
(Date:5/28/2015)... 2015  Eli Lilly and Company (NYSE: LLY ) ... tender offer for up to $1.6 billion aggregate principal amount ... of notes who tendered, and did not validly withdraw, their ... City time, on May 27, 2015 (the early ... are eligible to receive the total consideration. The total consideration ...
(Date:5/28/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report  "RNAi - ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... involves the use of double stranded RNA ... is processed into short 21-23 nucleotide RNAs ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
Cached News: